Rollout Map
Sign Up
S. 1095 Senate Health

Stop STALLING Act

Introduced
Mar 24, 2025
Sponsor
Sen. Klobuchar, Amy (D-MN)
View on Congress.gov

STAGE 3 OF 8 — CALENDARS AND SCHEDULING

Currently in the Senate. Last action: placed on senate legislative calendar under general orders. calendar no. 45 on Apr 10, 2025.

  1. Senate Introduced in Senate Mar 24, 2025
  2. Senate Read twice and referred to the Committee on the Judiciary. Mar 24, 2025
  3. Senate Committee on the Judiciary. Ordered to be reported without amendment favorably. Apr 3, 2025
  4. Senate Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report. Apr 10, 2025
  5. Senate Placed on Senate Legislative Calendar under General Orders. Calendar No. 45. Apr 10, 2025

Cosponsors

6

Subjects

Administrative remediesBusiness ethicsCivil actions and liabilityCompetition and antitrustDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Licensing and registrationsPrescription drugsPublic participation and lobbying

Committees

  • Judiciary Committee
    • [Reported By, Apr 10, 2025]
    • [Markup By, Apr 3, 2025]
    • [Referred To, Mar 24, 2025]

Summary

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

[Summary as of: Introduced in Senate]

Bill Text

Formatted Text PDF Formatted XML

Comments · 0

Loading comments...